Testosterone Enanthate Compounding Legal Status

FDA Approval History and Regulatory Classification

Testosterone enanthate received FDA approval in 1953 under NDA 009165, marketed as Delatestryl by Endo Pharmaceuticals. That makes it one of the longest-standing androgen therapies on the U.S. market. The drug is classified as a Schedule III controlled substance under the Controlled Substances Act, reflecting its potential for misuse and dependence 1.

Multiple generic manufacturers now produce injectable testosterone enanthate in sesame oil or cottonseed oil bases. The existence of commercially available, FDA-approved versions is a key regulatory fact. It directly shapes what compounding pharmacies can and cannot do with this molecule. The FDA considers a drug "commercially available" as long as at least one approved product remains on the market in adequate supply. Since testosterone enanthate has not appeared on the FDA Drug Shortage List in recent years, the commercial availability standard has remained intact.

The Testosterone Trials (TRT Trials), a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine (N=790 men aged 65 and older with serum testosterone <275 ng/dL), confirmed that testosterone treatment for one year improved sexual function, physical activity, and mood compared to placebo 2. These findings reinforced clinical demand for testosterone replacement therapy, and with that demand came increased interest in compounded formulations.

How Section 503A Governs Patient-Specific Compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), added by the 1997 FDA Modernization Act, permits licensed pharmacies to compound medications for individual patients based on a valid prescription from a licensed prescriber 3. The law was designed to allow pharmacists to fill therapeutic gaps. Not to create an alternative manufacturing pathway.

Three conditions must be met for 503A compounding of testosterone enanthate. First, the prescriber must document a clinical need that the commercial product does not satisfy, such as an allergy to the oil carrier (cottonseed or sesame) or a need for a concentration not commercially available. Second, the pharmacy cannot compound "regularly or in inordinate amounts" before receiving valid prescriptions. Third, the compounded product cannot be an "essentially a copy" of an FDA-approved drug unless that drug appears on the FDA shortage list.

The "essentially a copy" restriction is where most regulatory friction occurs. An intramuscular testosterone enanthate injection at 200 mg/mL in cottonseed oil would closely resemble the marketed generic product. A pharmacy compounding that exact formulation without a documented clinical difference risks FDA enforcement action. Pharmacies that alter the carrier oil (switching to grapeseed oil, for example) or compound a concentration like 250 mg/mL that is not commercially marketed may have a stronger argument for permissibility, though the FDA evaluates these claims case by case 3.

State boards of pharmacy add another layer. Compounding regulations vary by state, and some states impose stricter requirements than federal law. Texas and Florida, for example, maintain their own lists of drugs that pharmacies may or may not compound. Prescribers should verify their state board's position before writing a prescription intended for compounding.

Section 503B: Outsourcing Facilities and Bulk Production

Section 503B, created by the Drug Quality and Security Act of 2013 (DQSA), established a separate category called outsourcing facilities. These facilities can compound without individual patient prescriptions and distribute in bulk to healthcare providers, but they must register with the FDA, comply with current good manufacturing practice (cGMP) conditions, and submit to regular FDA inspections 4.

The 503B pathway matters for testosterone enanthate clinics that purchase compounded vials in advance for office-based injections. Before DQSA, many TRT clinics sourced multi-dose vials from traditional compounding pharmacies. That practice fell into a legal gray zone. Under 503B, an outsourcing facility can legally produce and ship testosterone enanthate in bulk quantities to a clinic, provided the facility meets all FDA registration and cGMP requirements.

FDA inspection records show that outsourcing facilities have received warning letters and Form 483 observations for sterility failures, potency deviations, and labeling deficiencies in compounded injectables including testosterone preparations 5. Between 2019 and 2024, at least four outsourcing facilities received enforcement actions related to injectable hormone products. Patients and prescribers can search the FDA's Registered Outsourcing Facilities list to verify a facility's status and inspection history.

The "Essentially a Copy" Doctrine in Practice

The FDA's "essentially a copy" standard is the single most contested issue in testosterone enanthate compounding. The agency published draft guidance in 2018 clarifying that a compounded drug is essentially a copy if it is identical or nearly identical to an approved drug in active ingredient, route of administration, dosage form, strength, and excipients 6.

For testosterone enanthate, this means a 200 mg/mL intramuscular injection in cottonseed oil would likely qualify as an essentially identical copy of the approved generic. A compounder who changes the vehicle to a different oil may argue the product is not a copy, but the FDA has stated that minor excipient changes alone do not necessarily exempt a product from this restriction.

Clinically, certain modifications carry genuine patient benefit. Patients with cottonseed or sesame oil allergies need an alternative carrier. Some clinicians prefer grapeseed oil for its lower reported injection-site reaction rate. Others prescribe subcutaneous testosterone enanthate at lower concentrations (100 mg/mL), a route and strength combination not available in any FDA-approved product as of May 2026. These represent the kinds of documented clinical differences that support lawful compounding under 503A 6.

Dr. Maria Felicetta, former FDA Associate Commissioner for Legislation, stated in testimony to the Senate HELP Committee: "Section 503A was never intended to create a parallel drug supply chain. It exists for the patients whom the commercial market cannot serve" 7.

What the Testosterone Enanthate Label Requires

The FDA-approved prescribing information for testosterone enanthate (Delatestryl) carries specific warnings and usage parameters that apply to both commercial and compounded products. The label specifies intramuscular injection only, with dosing of 50 to 400 mg every two to four weeks depending on the clinical indication 1.

Key label elements include a class-wide cardiovascular warning. In 2015, the FDA required all testosterone products to carry updated labeling about a possible increased risk of heart attack and stroke 8. This action followed a review of post-marketing adverse event reports showing signals for major adverse cardiovascular events (MACE) in men using testosterone, particularly those over 65 or with pre-existing cardiac risk factors.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was the first large cardiovascular outcomes trial specifically designed to assess testosterone replacement therapy. It found that testosterone cypionate (a closely related ester) did not significantly increase MACE incidence compared to placebo over a median follow-up of 33 months (hazard ratio 0.99; 95% CI, 0.81 to 1.21) 9. This trial has informed ongoing FDA label review discussions but has not yet resulted in label changes for testosterone enanthate.

The label also includes contraindications for men with breast cancer or known/suspected prostate cancer, women who are pregnant (Category X), and patients with serious cardiac, hepatic, or renal disease. These contraindications apply equally to compounded testosterone enanthate. A compounding pharmacy cannot remove or modify the contraindication profile simply because the product is not the branded version.

Prescribers ordering compounded testosterone enanthate should confirm that the pharmacy's label includes the approved drug name, strength, lot number, beyond-use date, and appropriate warnings. The USP <797> standards for sterile compounding also apply to the preparation process 10.

Safety Monitoring: Compounded vs. Commercial Products

Patients receiving compounded testosterone enanthate face the same pharmacologic risks as those using commercial products, plus additional risks related to compounding quality. Polycythemia (hematocrit above 54%) remains the most common laboratory adverse effect of TRT, occurring in approximately 5 to 15% of patients on injectable testosterone, depending on dose and individual response 11.

The Endocrine Society's 2018 Clinical Practice Guideline recommends monitoring hematocrit at 3 to 6 months after initiating testosterone therapy and annually thereafter, with dose reduction or phlebotomy if hematocrit exceeds 54% 11. Total testosterone levels should be measured midway between injections for enanthate, targeting a trough of 400 to 600 ng/dL in most patients. PSA screening and digital rectal examination remain advised at baseline and during follow-up in men over 40.

Dr. Shalender Bhasin, principal investigator of the Testosterone Trials, noted: "The decision to prescribe testosterone, whether branded or compounded, should rest on a confirmed diagnosis of hypogonadism with two morning testosterone levels below 300 ng/dL, combined with clinical symptoms" 2.

For compounded products specifically, potency variability is a concern the FDA has flagged. A 2017 FDA survey of compounded hormone products found that 34% of samples tested did not meet potency specifications, compared to less than 2% failure rates in FDA-approved products 5. Patients who notice unexpected changes in symptom control or side effects after switching between compounded lots should request potency testing of their current vial.

State-by-State Considerations for Compounded Testosterone

Each state board of pharmacy has jurisdiction over compounding practices within its borders, and the regulatory patchwork creates real clinical variability. Some states explicitly permit 503A compounding of testosterone enanthate with alternative carriers. Others have adopted more restrictive interpretations.

California's Board of Pharmacy requires compounding pharmacies to maintain a drug utilization review process and report compounding volumes for controlled substances quarterly. Florida's Board permits testosterone enanthate compounding but requires the prescriber to include "Compounding required" on the prescription along with the clinical reason the commercial product is inappropriate. Texas allows compounding of testosterone preparations but requires all compounded sterile products to be prepared in compliance with USP <797> and inspected by the state board at least biennially.

For telemedicine TRT providers, a critical question is whether the prescribing state, the patient's state, or the pharmacy's state governs. The answer depends on the specific state statutes involved. Most legal analyses default to the pharmacy's state for compounding practice standards and the patient's state for prescribing authority. Providers operating across state lines should consult pharmacy law counsel before establishing a compounding supply chain.

Emerging Regulatory Developments

The FDA continues to refine its compounding framework. The MOU between FDA and state boards of pharmacy, finalized in 2020, addresses interstate distribution of 503A-compounded products. States that sign the MOU agree to investigate complaints about pharmacies distributing compounded drugs out of state and to share information with the FDA. As of May 2026, most states have signed or adopted the MOU 12.

New USP <797> revisions, with an anticipated implementation date in late 2026, will tighten requirements for beyond-use dating, environmental monitoring, and personnel qualifications in sterile compounding. These changes could increase costs for pharmacies compounding testosterone enanthate and may reduce the number of pharmacies offering the product. Patients currently sourcing compounded testosterone should discuss contingency plans with their prescriber in case their pharmacy exits the sterile compounding market.

The Endocrine Society's updated hypogonadism guideline, expected in 2026, may further clarify recommendations on compounded vs. commercial testosterone products based on the TRAVERSE trial data and ongoing post-marketing surveillance 9.

Patients on compounded testosterone enanthate should have their hematocrit checked within 3 months of any lot change and should confirm their pharmacy's FDA registration status at FDA.gov/compounding at least annually.